{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:32:23Z","timestamp":1788582743575,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,22]],"date-time":"2020-03-22T00:00:00Z","timestamp":1584835200000},"content-version":"am","delay-in-days":326,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["18ZR1405600"],"award-info":[{"award-number":["18ZR1405600"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Foundation of Huashan Hospital","award":["HSBY2016016"],"award-info":[{"award-number":["HSBY2016016"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800529"],"award-info":[{"award-number":["81800529"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672009"],"award-info":[{"award-number":["81672009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Science and Technology Special Project of China","award":["2017ZX10202202-001"],"award-info":[{"award-number":["2017ZX10202202-001"]}]},{"name":"Major Science and Technology Special Project of China","award":["2017ZX10202203-007-002"],"award-info":[{"award-number":["2017ZX10202203-007-002"]}]},{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["AI094474"],"award-info":[{"award-number":["AI094474"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["AI110762"],"award-info":[{"award-number":["AI110762"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["AI123271"],"award-info":[{"award-number":["AI123271"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["AI134818"],"award-info":[{"award-number":["AI134818"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.antiviral.2019.03.006","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T18:24:11Z","timestamp":1553019851000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate"],"prefix":"10.1016","volume":"165","author":[{"given":"Yongmei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5108-2072","authenticated-orcid":false,"given":"Junjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.03.006_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136728","article-title":"Substitution at rt269 in hepatitis B virus polymerase is a compensatory mutation associated with multi-drug resistance","volume":"10","author":"Ahn","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.006_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.510270628","article-title":"Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine clinical investigation group","volume":"27","author":"Allen","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.03.006_bib3","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.29509","article-title":"A research agenda for curing chronic hepatitis B virus infection","volume":"67","author":"Alter","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.03.006_bib4","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1002\/j.1460-2075.1992.tb05420.x","article-title":"Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral-Rna genome","volume":"11","author":"Bartenschlager","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2019.03.006_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.antiviral.2017.06.016","article-title":"Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype A-H clinical isolates and core site-directed mutants in vitro","volume":"144","author":"Berke","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.03.006_bib6","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1128\/jvi.64.7.3319-3330.1990","article-title":"Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein","volume":"64","author":"Birnbaum","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cld.2007.08.002","article-title":"Molecular virology of hepatitis B virus for clinicians","volume":"11","author":"Block","year":"2007","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.antiviral.2019.03.006_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/386088a0","article-title":"Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy","volume":"386","author":"Bottcher","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.03.006_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-62703-484-5_13","article-title":"A southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures","volume":"1030","author":"Cai","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2016.05.005","article-title":"Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators","volume":"132","author":"Cai","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.03.006_bib11","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1128\/JVI.00582-13","article-title":"Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids","volume":"87","author":"Campagna","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib12","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.1128\/JVI.78.17.9538-9543.2004","article-title":"Hepatitis B virus capsid assembly is enhanced by naturally occurring mutation F97L","volume":"78","author":"Ceres","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib13","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1128\/JVI.77.13.7673-7676.2003","article-title":"Coexistence of two distinct secretion mutations (P5T and I97L) in hepatitis B virus core produces a wild-type pattern of secretion","volume":"77","author":"Chua","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.antiviral.2018.07.011","article-title":"Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro","volume":"158","author":"Corcuera","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.03.006_bib16","doi-asserted-by":"crossref","first-page":"10064","DOI":"10.1128\/JVI.01481-15","article-title":"Alteration of mature nucleocapsid and enhancement of covalently closed circular DNA formation by hepatitis B virus core mutants defective in complete-virion formation","volume":"89","author":"Cui","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib17","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1128\/AAC.46.9.3057-3060.2002","article-title":"Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro","volume":"46","author":"Delaney","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.03.006_bib18","doi-asserted-by":"crossref","first-page":"11833","DOI":"10.1128\/JVI.77.21.11833-11841.2003","article-title":"The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro","volume":"77","author":"Delaney","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.03.006_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2007.06.014","article-title":"The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging","volume":"76","author":"Feld","year":"2007","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.03.006_bib21","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1053\/j.gastro.2007.02.039","article-title":"Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B","volume":"132","author":"Ghany","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.03.006_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","article-title":"Selection of chronic hepatitis B therapy with high barrier to resistance","volume":"12","author":"Gish","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.006_bib23","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1128\/jvi.69.9.5437-5444.1995","article-title":"A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients","volume":"69","author":"Gunther","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/JVI.02008-08","article-title":"Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells","volume":"83","author":"Guo","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib25","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.1128\/JVI.01123-07","article-title":"Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation","volume":"81","author":"Guo","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/v9030056","article-title":"Complete and incomplete hepatitis B virus particles: formation, function, and application","volume":"9","author":"Hu","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.03.006_bib27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcv.2012.02.003","article-title":"The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation","volume":"54","author":"Ji","year":"2012","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib28","doi-asserted-by":"crossref","first-page":"15196","DOI":"10.1073\/pnas.1513803112","article-title":"High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein","volume":"112","author":"Klumpp","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2019.03.006_bib29","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2017.10.017","article-title":"Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs entecavir in uPA\/SCID mice with humanized livers and HBV infection","volume":"154","author":"Klumpp","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.03.006_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00835-18","article-title":"Novel potent capsid assembly modulators regulate multiple steps of the Hepatitis B virus life-cycle","volume":"62","author":"Lahlali","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.03.006_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00680-17","article-title":"Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants","volume":"61","author":"Lam","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2019.03.006_bib32","doi-asserted-by":"crossref","first-page":"i18","DOI":"10.1136\/gutjnl-2012-302085","article-title":"New perspectives in the therapy of chronic hepatitis B","volume":"61","author":"Lampertico","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2019.03.006_bib33","doi-asserted-by":"crossref","first-page":"9099","DOI":"10.1128\/JVI.74.19.9099-9105.2000","article-title":"Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein","volume":"74","author":"Le Pogam","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/dkr416","article-title":"Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy","volume":"67","author":"Lin","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2019.03.006_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006296","article-title":"Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA","volume":"13","author":"Liu","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.006_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00082-18","article-title":"Preclinical profile of AB-423, an inhibitor of hepatitis B virus pregenomic RNA encapsidation","volume":"62","author":"Mani","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.03.006_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003494","article-title":"Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein","volume":"9","author":"Mao","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.006_bib38","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1128\/JVI.01998-10","article-title":"Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells","volume":"85","author":"Mao","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib39","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/hep.510270243","article-title":"Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective","volume":"27","author":"Melegari","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.03.006_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00272-18","article-title":"Common and distinct capsid and surface protein requirements for secretion of complete and genome-free hepatitis B virions","volume":"92","author":"Ning","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1172\/JCI11100","article-title":"The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance","volume":"107","author":"Ono","year":"2001","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.antiviral.2019.03.006_bib42","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1128\/JVI.02033-09","article-title":"Conformational changes in the hepatitis B virus core protein are consistent with a role for allostery in virus assembly","volume":"84","author":"Packianathan","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib43","doi-asserted-by":"crossref","first-page":"11616","DOI":"10.1128\/JVI.01178-09","article-title":"Functional surfaces of the hepatitis B virus capsid","volume":"83","author":"Pairan","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hep.510290119","article-title":"Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance","volume":"29","author":"Pichoud","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.03.006_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01082-18","article-title":"Assembly properties of Hepatitis B Virus core protein mutants correlate with their resistance to assembly-directed antivirals","volume":"92","author":"Ruan","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2893.2005.00713.x","article-title":"Mutations affecting the replication capacity of the hepatitis B virus","volume":"13","author":"Sheldon","year":"2006","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2019.03.006_bib47","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1128\/JVI.76.23.12069-12077.2002","article-title":"Replication advantage and host factor-independent phenotypes attributable to a common naturally occurring capsid mutation (I97L) in human hepatitis B virus","volume":"76","author":"Suk","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib48","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0092-8674(82)90157-X","article-title":"Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate","volume":"29","author":"Summers","year":"1982","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2019.03.006_bib49","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","article-title":"Overview of hepatitis B viral replication and genetic variability","volume":"64","author":"Tong","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib50","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.febslet.2007.01.024","article-title":"Mutational analysis revealed that conservation of hepatitis B virus reverse transcriptase residue 306 (rtP306) is crucial for encapsidation of pregenomic RNA","volume":"581","author":"Wang","year":"2007","journal-title":"FEBS Lett."},{"key":"10.1016\/j.antiviral.2019.03.006_bib51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.virusres.2010.10.018","article-title":"Characterization of hepatitis virus B isolated from a multi-drug refractory patient","volume":"155","author":"Wei","year":"2011","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2019.03.006_bib52","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1128\/AAC.01091-13","article-title":"Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly","volume":"57","author":"Wu","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.03.006_bib53","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S1097-2765(01)80009-5","article-title":"The crystal structure of the human hepatitis B virus capsid","volume":"3","author":"Wynne","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.antiviral.2019.03.006_bib54","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-1-4939-6700-1_15","article-title":"Detection of hepatitis B virus particles released from cultured cells by particle gel assay","volume":"1540","author":"Yan","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib55","doi-asserted-by":"crossref","first-page":"9200","DOI":"10.1128\/JVI.00933-15","article-title":"The interferon-inducible protein tetherin inhibits hepatitis B virus virion secretion","volume":"89","author":"Yan","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib56","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jmv.22067","article-title":"T1846 and A\/G1913 are associated with acute on chronic liver failure in patients infected with hepatitis B virus genotypes B and C","volume":"83","author":"Yan","year":"2011","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib57","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2174\/0929867324666170704121800","article-title":"Small molecule inhibitors of hepatitis B virus nucleocapsid assembly: a new approach to treat chronic HBV infection","volume":"25","author":"Yang","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.006_bib58","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1128\/JVI.73.7.5731-5740.1999","article-title":"The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen","volume":"73","author":"Yuan","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib59","doi-asserted-by":"crossref","first-page":"10122","DOI":"10.1128\/JVI.73.12.10122-10128.1999","article-title":"Subtype-independent immature secretion and subtype-dependent replication deficiency of a highly frequent, naturally occurring mutation of human hepatitis B virus core antigen","volume":"73","author":"Yuan","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib60","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.12445","article-title":"Association of hepatitis B virus mutations of A1846T and C1913A\/G with acute-on-chronic liver failure development from different underlying chronic liver diseases","volume":"13","author":"Zhang","year":"2013","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.antiviral.2019.03.006_bib61","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jmv.20453","article-title":"High replicative full-length lamivudine-resistant hepatitis B virus isolated during acute exacerbations","volume":"77","author":"Zhang","year":"2005","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2019.03.006_bib62","doi-asserted-by":"crossref","first-page":"42374","DOI":"10.1038\/srep42374","article-title":"Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.03.006_bib63","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021501","article-title":"Antiviral therapies and prospects for a cure of chronic hepatitis B","volume":"5","author":"Zoulim","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.antiviral.2019.03.006_bib64","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:27:45Z","timestamp":1759062465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218305813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":63,"alternative-id":["S0166354218305813"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.03.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}